HK Stock Market Move | ASCLETIS-B (01672) opened nearly 15% higher. Positive topline results were obtained from the 13-week Phase II study of ASC30 for the treatment of obesity.

ASCLETIS-B(01672) opened nearly 15% higher, and as of the time of publication, it was up 14.93% at HKD 16.47, with a trading volume of HKD 10.73 million. On the news front, GeLi Pharmaceuticals announced that the Phase II study (NCT07002905) evaluating the oral small molecule GLP-1 receptor (GLP-1R) agonist ASC30 for the treatment of obesity has achieved positive topline results. In addition to achieving statistically significant and clinically meaningful weight loss, ASC30 also met secondary and exploratory endpoints. ASC30 significantly reduced several known cardiovascular risk markers in all dose groups, including total cholesterol, low-density lipoprotein cholesterol (LDL-C), triglycerides, as well as systolic and diastolic blood pressure. In steady state, blood levels of ASC30 increased with increasing doses.